.jpg?w=2580&hash=D5ACF3C857A94A4861D1166122105731)
Saturday, July 12
Sunday, July 13
Monday, July 14
Please Note: If you consent to have your badge scanned by a sponsor or at a sponsor-branded session, you are requesting Endocrine Society share your information - as it was provided during the registration process - with that sponsor so they may contact you for marketing purposes. This is optional - you may choose not to offer your badge. Please be aware that providing the sponsor with your information may involve transferring it to another country. For questions about how the sponsor will handle your information or to unsubscribe from their marketing communications, please contact the sponsor directly or refer to its privacy policy. For questions related to how the Endocrine Society shares information, please refer to The Society's Privacy Policy.
Join esteemed endocrinologists Dr. Diego Ferone (University of Genoa) and Dr. Joanna Spencer-Segal (University of Michigan), the lead authors on ACROINNOVA 1 and 2 respectively, for an engaging and interactive symposium focused on the evolving treatment landscape of acromegaly.
This educational session will highlight the latest clinical data on CAM-2029 from the ACROINNOVA clinical trial program, offering valuable insights into the efficacy, safety, and potential clinical impact of this emerging treatment option.
Through a real-world patient case study from the trial, Drs. Ferone and Spencer-Segal will explore practical considerations for integrating new treatments into clinical practice, emphasizing a patient-centered approach to disease management.
Following the case presentation, an expert-led roundtable discussion will provide a forum to examine key clinical takeaways, address patient selection criteria, and discuss treatment optimization strategies. The session will conclude with an interactive Q&A, where audience members will have the opportunity to engage directly with the speakers.
Don’t miss this opportunity to gain practical, real-world insights on the evolving landscape of acromegaly treatment from two of the field’s foremost experts.
Speakers:
Diego Ferone, MD, PhD
Joanna Spencer-Segal, MD, PhD
Join Xeris Pharmaceuticals® for a discussion on Cushing’s syndrome and results from LOGICS and SONICS. This program will delve into the consequences of excess cortisol, clinical guidelines for testing and diagnosis, and the importance of addressing the root problem – excess cortisol – to help manage Cushing’s syndrome symptoms and comorbidities. Attendees will gain insights into a pharmacotherapy option with clinical evidence spanning various severities and underlying causes of Cushing’s syndrome.
Speakers:
Eugenio Angueira, MD
Emily A., Patient Advocate
Discover the latest advancements in the treatment of Prader-Willi syndrome (PWS), featuring VYKAT XR—the first and only FDA-approved therapy specifically indicated for hyperphagia in adults and pediatric patients 4 years and older with PWS.
PWS is a rare genetic disorder, often beginning with failure to thrive in infancy, followed by the onset of hyperphagia in early childhood. This persistent, intense hunger affects nearly all individuals with PWS.
Join us for a peer-led session covering:
Don’t miss this opportunity to learn from experts and gain a firsthand perspective on managing hyperphagia in PWS.
Speaker:
Jorge Mejia Corletto, MD, FAAP
Learn about tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, the active ingredient in Zepbound® (tirzepatide) and Mounjaro® (tirzepatide). In this program, we will review clinical efficacy, safety, and dosing and administration information about Zepbound and Mounjaro. Attendees will have the opportunity to ask questions to the speaker at the conclusion of the program. Please see the Important Safety Information for Zepbound, including Boxed Warning, the full Prescribing Information, and Medication Guide provided at the product theater and available on www.zepbound.lilly.com/hcp. Please see the Important Safety Information for Mounjaro, including Boxed Warning, the full Prescribing Information, and Medication Guide provided at the product theater and available on www.mounjaro.lilly.com/hcp. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Mounjaro® and Zepbound® and their delivery device bases are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Speaker:
Steve Edelman, MD
Discover how data from the CATALYST study is reshaping clinical practice, with impact on hyperglycemia management and patient outcomes in endogenous hypercortisolism.
Speakers:
Richard Auchus, MD, PhD
Ralph DeFronzo, MD
Christopher Lucci, MD
Join our team of nationally recognized endocrinologists as they present the latest insights in the treatment of hypothyroidism, with a particular focus on the evolving role of desiccated thyroid extract (DTE). The program explores the clinical, physiological, and data-driven aspects of hypothyroidism management through expert-led presentations, highlighting the increasing importance of personalized treatment approaches. This program aims to equip healthcare professionals with the knowledge needed to optimize patient outcomes in the management of hypothyroidism.
Speakers:
Elizabeth McAninch, MD
Thanh Hoang, DO, FACP, FACE
This interactive program will focus on understanding the signs and symptoms of endogenous hypercortisolemia in patients with Cushing’s syndrome. Attendees will gain a greater appreciation of the clinical burden of hypercortisolemia and treatment approaches to improve outcomes.
Speakers:
Anthony Heaney, MD
Elena Christofides, MD
Divya Yogi-Morren, MD
Highlight factors beyond BMD which contribute to fracture risk •Risk of PMO•Bone architecture & strength •Professional recommendations: ASBMR Position statement, Criteria for VHFR where anabolic should be initial therapy •Dual mechanism of action •EVENITY® data: FRAME & ARCH
Speakers:
Steven Harris, MD
This presentation will review the underlying metabolic dysfunction in patients with MASH (metabolic dysfunction-associated steatohepatitis) and the impact of this dysfunction on disease progression. We will also review current AACE guidelines regarding patient identification, screening, and disease management techniques.
Speaker:
Marcelo Kugelmas, MD, FACP, FAASLD
Sunday, July 13
9:30–10:30 AM PT
Theater #2
Sponsor: Ascendis Pharma
A patient account of their experience with hypoparathyroidism, an overview of missing PTH being the underlying cause of hypoparathyroidism, as well as a review of an innovative treatment, including its mechanism of action, key efficacy and safety findings from the pivotal trail, as well as select dosing and titration information.
Speakers:
Joanna Maxwell
Tamara Vokes, MD
Expanded information on T1D patient journey with emphasis on disease management, monitoring pre-symptomatic T1D, and care coordination.
Speaker:
Gary Scheiner, MS, CDCES
Join us for a presentation on the long-term clinical trial data for Sogroya® (somapacitan-beco) 5, 10, or 15 mg. Following the clinical presentation, patient and caregiver ambassadors will share their stories about the journey from diagnosis to treatment and how Sogroya® has affected their lives.
Speakers:
Alicia Romano
Ryan and Megan - Patient Ambassadors
Join us for a discussion on the updated international X-linked hypophosphatemia (XLH) guidelines where we will discuss the clinical implications for diagnosis, evaluation, and multidisciplinary management of this disease. This program is sponsored by Kyowa Kirin, Inc. and is intended for US-based health care providers.
Speakers:
Steven Petak, MD, MACE, JD
E. Lewiecki, MD
Learn practical aspects of Thyroid Eye Disease (TED) patient identification, diagnosis, and disease management for endocrine specialists. This presentation is intended for US-based healthcare professionals.
Speaker:
Sherwin D'Souza, MD, FACE
.png?h=75&w=350&hash=13932070AE3F00FECD4768F5C0EE1ADB){kind=logo}
In this presentation, Veracyte's Medical Director of Endocrinology, Dr. Klopper, will describe how Afirma's whole-exome molecular analysis provides accurate and reproducible results to help in thyroid nodule management, and represents a platform for novel research opportunities.
Speaker:
Joshua Klopper, MD
Learn from an expert discussing perinatal/infantile- and juvenile-onset hypophosphatasia (HPP), treatment management, and how to approach your patients’ care.
Speaker:
Steven Petak, MD, MACE, JD
.png?h=65&w=350&hash=CEF2BF994DDE3839F83C805E0E896A53){kind=logo}
Join a presentation from the lead authors of CAHtalyst™ Adult and Pediatric to learn about CRENESSITY (crinecerfont), the first and only CRF1 antagonist for classic CAH . CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH). This presentation will include a review of clinical efficacy and safety results, and a discussion of the speakers’ clinical experience with CRENESSITY. Attendees will have the opportunity to pose questions to the speakers at the end of the session.
Speakers:
Richard Auchus, MD, PhD
Kyriakie Sarafoglou, MD
Monday, July 14
9:30–10:30 AM PT
Theater #1
Grab a coffee and join us for a relaxed, fireside-style conversation about the importance of long-term management of acromegaly.
IGF-1 is a critical biomarker in the management of acromegaly, providing a reliable snapshot of disease activity and treatment effectiveness. It is essential to both short- and long-term clinical decision making. However, without consistent access to a well-validated IGF-1 assay, accurately evaluating disease control can be significantly more challenging.
This session will focus on best practices for achieving comprehensive disease control by addressing both biochemical targets and the ongoing burden of symptoms. Through expert presentation and moderated discussion, we will highlight the importance of integrating consistent IGF-1 monitoring with ongoing symptom assessment to guide effective, long-term management strategies.
Speakers:
Christian Strasburger, MD
Shlomo Melmed, MB, ChB
This interactive, case-based presentation will provide an in-depth look at clinical data for a newly approved, non-glucocorticoid treatment for classic congenital adrenal hyperplasia (CAH) and will feature a clinical conversation about how to reduce glucocorticoids and manage androgens in real-world clinical practice. It will also provide a refresher on CAH pathophysiology and the impact of high androgens and chronic high dose glucocorticoid treatment in patients with CAH.
Speakers:
Natalie Nokoff, MD, PhD
Oksana Hamidi, DO
Christine Yedinak, MN, FNP, DNP
This presentation provides an overview of weight stigma, its negative effects on health, how it interferes with effective patient care, and strategies that can be implemented to reduce weight stigma and improve supportive healthcare delivery to patients of diverse body sizes. Collectively, the evidence is clear that medical professionals are not immune to weight stigma. When this stigma is present in healthcare interactions, the quality of patient care suffers. As most stigma-induced barriers to patient care occur in the context of clinician-patient interactions, this means that strategies to reduce weight stigma in healthcare must address how healthcare professionals communicate with patients. Through increased self-awareness and education about weight stigma, respectful language, supportive counseling, and patient-centered approaches, healthcare professionals can remove weight stigma from clinical care. You will learn key strategies to reduce weight stigma and improve care for patients of diverse body sizes.
Speaker:
Rebecca Pearl
Discussion on the complexities and challenges of acromegaly management, focusing on key barriers to optimal patient outcomes. The talk will explore the impact of delayed diagnosis, highlighting how the slow progression of symptoms and overlap with common conditions contribute to a diagnostic delay, that may lead to increased morbidity and complications. The session will also cover IGF-1 testing, including its importance, frequency, and assay variability. Challenges in achieving biochemical and symptom control will be addressed, emphasizing treatment goals, adherence issues such as injection fatigue, and the unmet need, including limitations of current therapies.
Speakers:
Scott Struthers, PhD
Lisa Nachtigall, MD
Laurence Katznelson, MD
Graves’ disease is an autoimmune disorder and the most common cause of hyperthyroidism, affecting approximately 2% of women and 0.2% of men worldwide. Current standard of care treatments have remained largely unchanged for over 70 years and aim to reduce or eliminate the production of thyroid hormones, rather than target the underlying autoimmune pathology that causes the disease.
During this program, Dr. Kotwal will review the significance of thyroid-stimulating hormone receptor–binding antibodies (TRAbs) in the development of Graves’ disease and their association with clinical outcomes. He will discuss the shifting trends in treatment choice and the primary goals among endocrinologists who are managing patients with Graves’ disease.
Dr. Kahaly will focus on the remaining unmet needs for patients with Graves’ disease, despite current treatment options. He will review how TRAb levels are normally maintained in the circulation by the neonatal Fc receptor (FcRn) and discuss the potential to target the underlying autoimmune response in Graves’ disease through FcRn inhibition. Dr. Kahaly will review the design of a global Phase 2b pivotal clinical trial investigating the FcRn inhibitor IMVT-1402, which is actively enrolling adult patients with Graves’ disease who remain hyperthyroid despite current therapy (ClinicalTrials.gov identifier: NCT06727604).
Speakers:
George Kahaly, MD, PhD
Anupam Kotwal, MD, MSc, FACE, FRCP (Edin)
Acquired hypothalamic obesity is a unique form of rapid-onset, severe obesity caused by an injury to the hypothalamus. It is most commonly caused by hypothalamic-pituitary tumors or treatments of those tumors such as surgery, radiation, but also can be caused by traumatic brain injury, inflammation due to infection etc. Apart from various endocrinopathies, this physical injury may impair the melanocortin 4 receptor (MC4R) pathway in the hypothalamus, which is critical in regulating hunger, caloric intake, energy expenditure and consequently regulating weight. Thus, an impairment in MC4R signaling may lead to hyperphagia, decreased energy expenditure, and accelerated and sustained weight gain. Please join us as we understand the role of the MC4R pathway in acquired hypothalamic obesity, recognize the burden of acquired hypothalamic obesity on patients and caregivers. Experts will discuss strategies to identify, diagnose and manage acquired hypothalamic obesity early in incident population as well as in prevalent populations that have had hypothalamic injury as part of their medical history.
Speakers:
Odelia Cooper, MD
Ilene Fennoy, MD, MPH
